Upper Saint Clair, PA, United States
Upper Saint Clair, PA, United States

Time filter

Source Type

Zamboni W.C.,University of North Carolina at Chapel Hill | Torchilin V.,Northeastern University | Patri A.K.,SAIC | Hrkach J.,BIND Biosciences | And 5 more authors.
Clinical Cancer Research | Year: 2012

Historically, treatment of patients with cancer using chemotherapeutic agents has been associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be administered without toxic solvents. They hold immense potential in addressing all of these issues, which has hampered further development of chemotherapeutics. Furthermore, such drug delivery systems will lead to cancer therapeutic modalities that are not only less toxic to the patient but also significantly more efficacious. In addition to established therapeutic modes of action, nanomaterials are opening up entirely new modalities of cancer therapy, such as photodynamic and hyperthermia treatments. Furthermore, nanoparticle carriers are also capable of addressing several drug delivery problems that could not be effectively solved in the past and include overcoming formulation issues, multidrug-resistance phenomenon, and penetrating cellular barriers that may limit device accessibility to intended targets, such as the blood-brain barrier. The challenges in optimizing design of nanoparticles tailored to specific tumor indications still remain; however, it is clear that nanoscale devices carry a significant promise toward new ways of diagnosing and treating cancer. This review focuses on future prospects of using nanotechnology in cancer applications and discusses practices and methodologies used in the development and translation of nanotechnology-based therapeutics. ©2012 AACR.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-2.3.2-3 | Award Amount: 17.07M | Year: 2010

This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of resistance. The proposal includes development of both slow release and gel formulations, pharmacokinetic and challenge experiments in macaques as well as human studies including a collaborative study with an EDCTP-funded project to use multiplex and proteomic technologies as well as culture-independent DNA-based analysis of mucosal microbiota to investigate biomarkers and establish a baseline signature from which perturbations can be recognised. This is a large consortium comprising 30 partners from 8 EU countries and from Switzerland, Ukraine, South Africa and the United States.Partners include microbicide developers, IPM and Particle Sciences, and producers, Gilead, Tibotec and Virco. Two SMEs will also participate in RTD aspects. The consortium is multidisciplinary with scientists engaged in basic discovery working with new targets and developing novel chemistry to produce compounds with improved safety and efficacy profiles as well as altered patterns of resistance.


CLEVELAND, November 14, 2016 -The Lubrizol Corporation's LifeSciences business, a leading supplier of services and advanced materials for the pharmaceutical and medical device industry, announces it will showcase its expanded range of solutions for the pharmaceutical industry at the 2016 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition November 14 -17 at the Colorado Convention Center in Denver, Colorado (Booth #1127). Lubrizol LifeSciences will highlight the drug product development capabilities of Particle Sciences - a leading contract drug development and manufacturing organization with a comprehensive suite of services for the formulation, analysis and production of complex drug delivery solutions. Lubrizol LifeSciences continues to expand its capabilities at Particle Sciences, providing full service cGMP drug product development and manufacturing across a variety of sterile and non-sterile complex dosage forms such as micro/nano-particulates, emulsions and drug-eluting devices. "With the new investment in over 2,700 ft2 of commercial cleanroom space, we continue to demonstrate our commitment to be the leading CDMO for complex drug products.  Our organization has a depth of knowledge and resources found nowhere else," stated Mark Mitchnick M.D., CEO, Particle Sciences Inc., chief medical officer, Lubrizol LifeSciences. Lubrizol LifeSciences' newest product, Transform(TM), is the only hydrate-able topical film that offers wide API compatibility, value and convenience all in one. Transform films make loading APIs for drug delivery fast and easy. This can eliminate additional raw materials and processing steps of lamination and multiple components. Improved patient comfort is another benefit as Transform is a cool, comfortable, transparent film designed for optimal aesthetics and therapeutic benefit. Lubrizol LifeSciences is a healthcare solution partner that provides customer support from idea to execution by supplying customizable polymers and excipients, complex drug formulation development and best-in-class contract manufacturing services for medical device and pharmaceutical manufacturers. The combination of our polymer expertise, drug formulation development and quality contract manufacturing allows LifeSciences to offer our customers end-to-end solutions for success in the drug delivery market. Particle Sciences, now part of Lubrizol LifeSciences, is an integrated provider of drug development and manufacturing services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development and manufacturing solution that minimizes the time and risk between discovery and commercialization. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information. The Lubrizol Corporation, a Berkshire Hathaway company, is a technology-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care and personal care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions. Our products for the oilfield market include technologies for exploration, production and transportation. With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world.  Founded in 1928, Lubrizol has approximately 9,000 employees worldwide. Revenues for 2015 were $7 billion. For more information, visit Lubrizol.com. Particle Sciences is part of Lubrizol Advanced Materials, Inc. Transform(TM) is a trademark of The Lubrizol Corporation.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.2.3.2-3 | Award Amount: 7.61M | Year: 2012

The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized development of anti-retroviral (ARV)-based microbicides. Combining ARVs in a single product may provide increased protection. Development of a generally applicable formulation platform for combining ARVs (even if chemically incompatible) and understanding of the processes (drug uptake, efflux and metabolism) that determine tissue levels of microbicide are two important gaps in knowledge necessary for microbicide development. We propose to identify drug uptake and efflux transporters in cervicovaginal tissue and to use this information together with data on drug transporters from colorectal tissue to develop improved in vitro cell-based systems for biopharmaceutical screening. We also propose to develop a standardized drug encapsulation and formulation system that will allow insertion of any drug combinations. Informed by data on drug uptake, efflux and metabolism, these formulations will be further modified either by beneficial drug-drug interactions or by including selective inhibitors or inducers of drug transporters to optimize drug concentrations at target tissue sites. Comparative studies of drug transporters will also be performed in two important animal models, namely non-human primates (virus challenge ) and rabbit (regulatory toxicology). Optimised drug formulations will be tested in vitro and will undergo pharmacokinetic and pharmacodynamics studies in the animal models. Project outcomes will include a detailed description of drug transport in colorectal and cervicovaginal tissue to provide a rational basis for microbicide formulation, platform technology for formulating microbicide combinations optimized for vaginal or rectal delivery and prototype microbicide products for phase I clinical trial. The proposal should impact significantly on development of improved microbicides to prevent HIV infection.

Loading Particle Sciences Inc. collaborators
Loading Particle Sciences Inc. collaborators